Research Funding of £1.26M granted to QV Bioelectronics for advancements in novel brain cancer therapy research
QV Bioelectronics, a UK-based biotechnology company, is making strides in the fight against brain cancer with its innovative GRACE (Glioblastoma Responsive AC Electric field) therapy. This non-invasive treatment approach, which uses low-intensity, alternating electric fields to disrupt cancer cell division specifically in brain tumors like glioblastoma, is currently in pre-clinical development.
The company has recently been awarded a 1.26 million GBP grant under the Biomedical Catalyst programme, a strong vote of confidence in their technology. This funding will support key preclinical, regulatory, and clinical readiness activities for GRACE, including device validation, safety testing, engagement with the MHRA and NHS Research Ethics Committee, formation of a clinical steering group, and preparations for an initial human study.
However, as of now, the first in human study for GRACE has yet to be initiated. The University of Edinburgh's statement does not specify a timeline for this milestone. The university, along with NHS Lothian, has contributed to the development of the GRACE project.
The CEO of QV Bioelectronics, Dr Christopher Bullock, expressed his satisfaction with the grant, stating that it is a strong vote of confidence in their technology. The company has reported 'encouraging' preclinical safety and efficacy data, holds multiple granted patents, and has secured over 6 million GBP in grant funding and equity investment.
Current treatments for brain cancer have limited effectiveness and poor outcomes, with glioblastoma having one of the poorest prognoses in oncology. GRACE's Electric Field Therapy targets tumor cells while sparing healthy tissue, making it a promising new approach to treating glioblastoma.
The University of Edinburgh's Clinical Director of Neurosurgery has stated that GRACE has the potential to significantly improve patient outcomes and quality of life. QV Bioelectronics aims to establish GRACE as a future first-line treatment for glioblastoma, with future potential in paediatric and metastatic brain tumours.
Despite the promising developments, a search for "QV Bioelectronics GRACE Electric Field Therapy" for brain tumors reveals limited information. The search results mainly list unrelated companies and organizations with no connection to this therapy. For detailed evidence or recent updates on preclinical studies and funding specifically for QV Bioelectronics' GRACE therapy, specialized biotech databases, company press releases, or scientific publications would be the best sources.
The University of Edinburgh is excited about the prospect of the first in human study for GRACE, marking a significant step towards making this innovative treatment available to patients.
- The grant awarded to QV Bioelectronics for its GRACE therapy indicates a promising future in the medical-conditions realm, particularly for cancer treatments, such as brain cancer, and health-and-wellness initiatives, as this innovative electric field therapy could significantly improve patient outcomes.
- The University of Edinburgh and NHS Lothian have played significant roles in the development of the GRACE project, a therapy that targets tumor cells while sparing healthy tissue, which has the potential to become a first-line treatment for brain cancer, including glioblastoma, and potentially for paediatric and metastatic brain tumors.
